Joshua Mansour, M.D., M.B.A.

Published Manuscripts

• Ong, S. Y., Pak, S., Mei, M., Wang, Y., Popplewell, L., Baird, J. H., Herrera, A. F., Shouse, G., Nikolaenko, L., Zain, J., Godfrey, J., Htut, M., Aribi, A., Spielberger, R., Mansour, J., Forman, S. J., Palmer, J., & Budde, L. E. (2023). Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma. American Journal of Hematology, 10.1002/ajh.27069. Advance online publication.
• Aldoss, I., Yang, D., Malki, M. M. A., Mei, M., Mokhtari, S., Artz, A., Cao, T., Salhotra, A., Ali, H., Aribi, A., Khaled, S., Arslan, S., Sandhu, K., Koller, P., Mansour, J., Spielberger, R., Stein, A., Snyder, D., Marcucci, G., Forman, S. J., … Pullarkat, V. (2021). Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies. Transplantation and cellular therapy,27(3), 255.e1–255.e9.
• Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies. Transplantation and Cellular Therapy. December 19, 2020.
• Overall survival of patients with triple‐class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. American Journal of Hematology. September 2020. DOI: 10.1002/ajh.26010
• Gandhi, U, Cornell, RF, Lakshman, A, Gahvari, Z, McGehee, E, Jagosky, MH, Gupta, R, Varnado, W, Fiala, MA, Chhabra, S, Malek, E, Mansour J, Paul, B, Barnstead, A, Kodali, S, Neppalli, A, Liedtke, M, Godby, KN, Kang, Y, Kansagra, A, Umyarova, E, Scott, EC, Hari, P, Vij, R, Usmani, SZ, Callander, NS, Kumar, SK, Costa, LJ. Outcomes of Patients with Multiple Myeloma Refractory to CD38 Targeted Monoclonal Antibody Therapy. Leukemia. September 2019. doi: 10.1038/s41375-019-0435-7.
• Mansour J, Rao, A, Shaheen, M, Yang, S, Ji-Hyun, L, Nordquist, H, Rixe, O. Increased bone remodeling on patients treated with a CTLA-4 inhibitor: First report of an unknown autoimmune reaction. Journal of Community and Supportive Oncology. August 2017.
• Mansour J, Brill, Mathew, Gourdin, Theodore. Rare Case of Spontaneous Tumor Lysis Syndrome (TLS) in a patient with Germ Cell Tumor (GCT): Literature Review and Approach to Management. MOJ Clinical Med Case Rep. July 2017. DOI: 10.15406/mojcr.2017.07.00190
• Mansour J, Mangaonkar, Kota, V. Recurrent Metastatic Parotid Carcinosarcoma in an Asymptomatic Patient. Journal of Investigative Medicine High Impact Case Reports. 2016 Nov 4;4(4):2324709616676590
• Mangaonkar, A, Xu, H, Mondal, A, Mansour, J, DeRemer, D, Clemmons, A, Chintalapally, R, Jillella, A, Kolhe, R, Kota, V. Prognostic value of complete remission with superior platelet counts in Acute Myeloid Leukemia. Journal of Community and Supportive Oncology. 2016 Feb;14(2):66-71. doi: 10.12788/jcso.0231
• Mansour J, Mangaonkar, A, Keen, R, Kukkadapu, T, Chintalapally, R, Kota, V. Pneumatosis Intestinalis in an Acute Promyelocytic Leukemia (APL) patient. Case Reports in Hematology. October 2015. 2015;2015:576042. doi: 10.1155/2015/576042. Epub 2015 Oct 8

Abstracts

• Gandhi, U, Cornell RF, Lakshman A, Gahvari Z, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ. Natural History of Patients with Multiple Myeloma Refractory to Elotuzumab and Outcomes of Subsequent Therapy with Anti-CD38 Monoclonal Antibodies. Abstract #112246. Poster Presentation. American Society of Hematology. December 2, 2018. San Diego Convention Center, Hall GH. Blood 2018 132:3303
• Gandhi U, Cornell RF, Lakshman A, Gahvari Z, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ. Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment. Abstract #111033. Poster Presentation. American Society of Hematology. December 2, 2018. San Diego Convention Center, Hall GH. Blood 2018 132:3233
• Gandhi U, Cornell RF, Lakshman A, Gahvari Z, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ. Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Treatment. Abstract #115078. Poster Presentation. American Society of Hematology. December 1, 2018. San Diego Convention Center, Hall GH. Blood 2018 132:2015
• Mansour J, Rao A, Shaheen M, Yang S, Ji-Hyun L, Nordquist H, Rixe O. Increased bone remodeling on patients treated with a CTLA-4 inhibitor: First report of an unknown autoimmune reaction. J Clin Oncol 33. June 2015 (suppl; abstr e14027).
• Mangaonkar A, Mohsin J, Mansour J, Kolhe R, Mondal A, Puttagunta H, Jillella A, Kota V. Day 30 Platelet Count as a Prognostic Marker of Survival in Acute Myeloid Leukemia. Blood 124 (21). December 2014.
• Mansour J, Mangaonkar A, Zakharia Y, Chand A, Jillella A, Kota V. Utility of D-Dimer As a Marker for Differentiation Syndrome and Infections in Acute Promyelocytic Leukemia (APL). Abstract #65814 Publication #4986. Blood. November 2013.
• Zakharia Y, Kota V, Mansour J, Prabhakar R, Lan L, Awan F, Jillella A. “Serum Alkaline Phosphatase Level on Day 4 of G-CSF Administration Could Be a Simple Yet Practical Surrogate Marker for CD34 Mobilization and Collection.” Abstract # 65543 Publication #4519. Blood. November, 2013.